U.S. Patent 6,689,275: Claim Scope, Expiration, and Ferric Pyrophosphate Dialysis Patent Landscape

U.S. Patent 6,689,275 covers the use of dissolved ferric pyrophosphate in peritoneal or hemodialysis solutions to deliver iron during dialysis. Its core protection is defined by four elements: the dialysis route, dissolved ferric pyrophosphate, specified iron concentrations, and safe iron administration or bioavailability. The patent term expired in approximately June 2021, so the claims no longer provide an enforceable U.S. exclusion right. Later patents directed to ferric pyrophosphate citrate formulations, dialysate delivery systems, and product-specific formulations may still affect current commercial products.

What does U.S. Patent 6,689,275 protect?

The patent protects a dialysis-based iron-delivery concept rather than a general ferric pyrophosphate composition.

Claim	Claim type	Required subject matter	Key quantitative limitation
1	Composition	Ferric pyrophosphate dissolved in a peritoneal dialysis or hemodialysis solution	No express concentration
2	Method	Increasing bioavailable iron during dialysis using ferric pyrophosphate dissolved in dialysis solution	2-50 micrograms iron per deciliter
3	Method	Administering iron to a dialysis patient through dialysis solution containing soluble ferric pyrophosphate	2-50 micrograms iron per deciliter
4	Method	Increasing bioavailable iron during hemodialysis using dissolved ferric pyrophosphate	4-50 milligrams iron per dialysis session

The claims do not cover every iron-containing dialysis solution. A potentially infringing product would generally need to use ferric pyrophosphate in dissolved form and satisfy the applicable dialysis, concentration, or dosing limitations.

How should claim 1 be construed?

Claim 1 is a composition claim with four principal limitations:

The composition contains ferric pyrophosphate.
The ferric pyrophosphate is dissolved in the dialysis solution.
The solution is a peritoneal dialysis solution or a hemodialysis solution.
The composition is not limited to a particular concentration, excipient, pH, container, or manufacturing process.

The word “dissolved” is important. A suspension, precipitate, particulate dispersion, or insoluble iron formulation would present a stronger noninfringement position than a formulation in which ferric pyrophosphate is molecularly or ionically present in solution.

The claim does not expressly require:

A particular dialysis machine;
A particular dialysis duration;
A specific iron dose;
A particular buffer;
A sterile container;
A particular ferric-to-pyrophosphate ratio beyond the identity of the claimed compound; or
A particular patient population.

The claim is therefore broad in formulation architecture but narrow as to the iron species and dialysis application.

What do claims 2 and 3 cover?

Claims 2 and 3 are closely related method claims. Both require delivery through dialysis solution and both specify 2-50 micrograms of iron per deciliter.

Claim 2

Claim 2 requires:

A mammal;
Dialysis treatment;
Administration through peritoneal dialysis solution or hemodialysis solution;
Ferric pyrophosphate as the iron source;
Dissolution in the dialysis solution;
An iron concentration of 2-50 micrograms per deciliter; and
An increase in bioavailable iron.

The “mammal” language is broader than a dialysis-patient limitation, although the administration route effectively narrows practical use to dialysis patients.

Claim 3

Claim 3 requires:

A dialysis patient;
Dialysis with the specified solution;
A solution containing 2-50 micrograms of iron per deciliter; and
Ferric pyrophosphate in soluble form.

Claim 3 does not expressly require an increase in bioavailable iron. It instead recites safe iron administration. That difference may matter in claim construction and infringement analysis because claim 3 focuses more directly on the administration step and formulation.

Claims 2 and 3 overlap substantially. Claim 2 covers increasing bioavailable iron in a mammal, while claim 3 is directed to administering iron to a dialysis patient. A commercial dialysate product could potentially satisfy both if it contains the required dissolved ferric pyrophosphate concentration.

What does claim 4 add?

Claim 4 is limited to hemodialysis and uses a total-session dose instead of a concentration range.

The claim requires:

A mammal undergoing hemodialysis;
Delivery through hemodialysis solution;
Ferric pyrophosphate in dissolved form;
4-50 milligrams of iron per dialysis session; and
A safe increase in bioavailable iron.

Claim 4 may capture products that satisfy the total-dose range even when the relevant commercial documentation emphasizes total iron delivered per treatment rather than iron concentration in dialysate.

The concentration and total-dose limitations can overlap. For example, a dialysate volume of 120 liters contains:

Iron concentration	Total iron in 120 liters
2 micrograms/dL	2.4 mg
10 micrograms/dL	12 mg
25 micrograms/dL	30 mg
50 micrograms/dL	60 mg

At a 120-liter dialysate volume, claim 4’s 4-50 milligram range corresponds approximately to 3.3-41.7 micrograms per deciliter. Actual infringement analysis would depend on the dialysate volume, the iron concentration, and whether the product delivers the claimed quantity during a single session.

When did U.S. Patent 6,689,275 expire?

U.S. Patent 6,689,275 issued on February 10, 2004. Its effective U.S. patent term ran approximately 20 years from the relevant nonprovisional filing date and expired in June 2021, subject to any applicable patent-term adjustment or extension recorded in the USPTO patent file.[1]

The patent is therefore no longer an enforceable U.S. patent based on ordinary term expiration. A party cannot bring a new U.S. infringement action based solely on commercial activity occurring after expiration. Activities conducted during the enforceable term may present separate limitations issues, including statute-of-limitations and damages questions.

Did FDA regulatory exclusivity extend the patent?

No. FDA regulatory exclusivity and patent term are separate rights. Approval of a ferric pyrophosphate dialysis product could provide New Drug Application exclusivity, but FDA exclusivity does not revive an expired patent or extend its enforceability under the Patent Act.[2]

What is the Orange Book status of U.S. Patent 6,689,275?

U.S. Patent 6,689,275 should not be treated as a current Orange Book barrier because its patent term expired in 2021.

The Orange Book records patents and regulatory exclusivity associated with approved drug products, but listing does not extend a patent beyond its statutory term. A patent listed for an approved ferric pyrophosphate product would have to be analyzed separately from U.S. 6,689,275. The relevant questions are whether the patent remains unexpired, whether it is listed against the applicable NDA, and whether the proposed generic product is covered by the listed claims.[3]

For current market analysis, U.S. 6,689,275 is best classified as:

Issue	Status
Patent term	Expired in approximately June 2021
Current enforceability	None based on ordinary patent term
Orange Book relevance	Historical or informational only
Paragraph IV risk from this patent	None for a current filing because the patent is expired
Freedom-to-operate value	Limited as a blocking right; substantial as prior art

Which later patents may affect ferric pyrophosphate dialysis products?

The post-2000 patent landscape shifted from broad dialysis delivery concepts toward more specific products and formulations. The principal areas of later patent activity include:

Ferric pyrophosphate citrate formulations

Later patents associated with ferric pyrophosphate citrate products generally focus on:

A soluble ferric pyrophosphate citrate complex;
Defined iron-to-citrate or iron-to-pyrophosphate relationships;
Stability in bicarbonate-containing dialysate;
Concentrated liquid or powder formulations;
Compatibility with hemodialysis machines; and
Delivery of iron through dialysate or replacement fluid.

These claims may be narrower chemically than claim 1 of U.S. 6,689,275 but can remain commercially important because a marketed product may use ferric pyrophosphate citrate rather than the unqualified ferric pyrophosphate form recited in the older patent.

Product and delivery-system patents

Later patent families may cover:

A cartridge or container that introduces iron into dialysate;
A dry powder mixed with dialysate before treatment;
A liquid concentrate added upstream of the dialyzer;
Automated dosing based on dialysate flow rate;
Formulations designed for single-use administration; and
Storage-stable iron compositions.

These rights can create barriers even when U.S. 6,689,275 is expired. A generic or competing product may avoid the expired patent but still require a noninfringement position against later formulation, container, or dosing patents.

Method-of-use patents

Method claims may cover:

Maintaining hemoglobin or reticulocyte parameters;
Replacing iron lost during hemodialysis;
Reducing the need for intravenous iron;
Administering iron continuously during treatment;
Treating iron deficiency in chronic kidney disease; and
Use in patients receiving erythropoiesis-stimulating agents.

A product can avoid claim 1 yet encounter method-of-use risk if its label, promotional materials, or treatment protocol induces use covered by a later method patent.

What products are commercially associated with this patent area?

Rockwell Medical developed Triferic, an iron-replacement product based on ferric pyrophosphate citrate and designed for delivery through hemodialysate. The FDA approved Triferic in 2015 for maintaining hemoglobin in adult patients receiving chronic hemodialysis.[4] A later formulation, Triferic AVNU, was approved for intravenous administration and is distinct from the original dialysate-delivery product.[5]

The commercial distinction is material:

Product category	Administration route	Patent relevance
Ferric pyrophosphate in dialysate	Hemodialysis or peritoneal dialysis solution	Closest to U.S. 6,689,275
Ferric pyrophosphate citrate dialysate product	Hemodialysate	Potentially covered by later composition and use patents
Intravenous ferric pyrophosphate citrate	Intravenous infusion	Generally outside the literal dialysis-solution limitations
Conventional IV iron products	Intravenous injection or infusion	Not within the central claim structure of U.S. 6,689,275

The original patent’s expiration lowers the barrier for competing dialysate iron products. It does not eliminate later patent, regulatory, formulation, manufacturing, or market-access barriers.

Are there Paragraph IV challenges or patent litigation involving this patent?

Because U.S. 6,689,275 expired in 2021, a current Paragraph IV challenge would not be needed to clear that patent. A generic applicant could rely on expiration rather than certify that the patent is invalid or not infringed.

The principal litigation risks for current products would instead involve later unexpired patents directed to:

Ferric pyrophosphate citrate;
Specific formulations;
Dialysate-compatible iron concentrations;
Delivery containers or cartridges;
Manufacturing processes; and
Labeled methods of maintaining iron status during dialysis.

No current enforcement position can be based solely on the expired claims of U.S. 6,689,275. Any historical litigation involving the patent would need to be assessed separately for claim construction, validity, infringement period, settlement terms, and damages exposure.

How strong is the patent estate for a competing dialysis iron product?

The estate surrounding the original invention is strong as prior art but weak as an active blocking right.

Factor	Assessment
Broad concept of iron delivery through dialysate	No current exclusion right from U.S. 6,689,275
Dissolved ferric pyrophosphate	Historically broad claim scope
Ferric pyrophosphate citrate products	Potential later-patent exposure
Dialysate dosing systems	Potential device and formulation exposure
Method-of-use claims	Depends on product labeling and treatment instructions
Manufacturing know-how	May remain commercially relevant even without patent protection
Biosimilar risk	Not applicable in the conventional biologic sense
Generic risk	Higher after expiration, subject to later patents and FDA requirements

“Biosimilar risk” is not the primary framework because ferric pyrophosphate dialysis products are small-molecule or chemical drug products, not biologics regulated through the biosimilar pathway. The relevant competitive routes are generally an ANDA, a 505(b)(2) application, or a full NDA, depending on formulation, route, and reference-product differences.[6]

What generic launch scenarios exist?

A competitor could pursue several launch strategies:

A conventional generic or follow-on dialysate additive using the same active iron concept, relying on expiration of U.S. 6,689,275.
A redesigned ferric pyrophosphate formulation that avoids later composition claims.
A different iron complex delivered through dialysate.
A 505(b)(2) product with a modified formulation, concentration, container, or administration method.
A product directed to a different dialysis setting, such as peritoneal dialysis, if supported by clinical and regulatory data.

The main technical barriers are solubility, stability, compatibility with bicarbonate dialysate, iron bioavailability, precipitation control, sterilization, container compatibility, and reproducible dosing. These barriers may support trade-secret protection or later patent claims even though the foundational patent has expired.

What geographic rights remain?

U.S. Patent 6,689,275 provides no current U.S. patent exclusivity after expiration. Foreign counterparts must be analyzed independently because filing dates, national-phase prosecution, patent-term adjustments, supplementary protection certificates, maintenance fees, and invalidity outcomes vary by jurisdiction.

A company seeking global launch should separate:

U.S. freedom to operate after June 2021;
European patent-family status;
Canadian and Australian term status;
Japanese and Korean national rights;
Product-specific formulation patents; and
Regulatory exclusivity in each market.

A U.S. expiration does not establish freedom to operate in Europe or other jurisdictions.

Key Takeaways

U.S. Patent 6,689,275 covers dissolved ferric pyrophosphate in peritoneal or hemodialysis solution.
Claim 1 is a composition claim; claims 2-4 are dialysis iron-administration method claims.
Claims 2 and 3 require 2-50 micrograms of iron per deciliter.
Claim 4 requires 4-50 milligrams of iron per hemodialysis session.
The patent expired in approximately June 2021 and is not a current U.S. blocking patent.
The principal modern risks arise from later ferric pyrophosphate citrate, formulation, delivery-system, manufacturing, and method-of-use patents.
Triferic is the principal FDA-approved commercial product associated with dialysate-based ferric pyrophosphate citrate delivery.
Current competitors would generally face ANDA or 505(b)(2) analysis, not biosimilar regulation.
No current Paragraph IV challenge is needed to clear an expired patent.
Foreign family members and later continuation patents require separate jurisdiction-by-jurisdiction review.

FAQs: U.S. Patent 6,689,275 and Ferric Pyrophosphate Dialysis Products

Does U.S. Patent 6,689,275 cover intravenous ferric pyrophosphate?

No. The claims require administration through peritoneal dialysis solution or hemodialysis solution. An intravenous product would not literally satisfy those dialysis-solution limitations.

Does claim 1 require a particular iron concentration?

No. Claim 1 does not recite a concentration. The concentration limits appear in claims 2 and 3, while claim 4 uses a per-session dose range.

Can a product avoid the patent by using insoluble ferric pyrophosphate particles?

The product would have a stronger noninfringement position if the ferric pyrophosphate is not dissolved. The claim expressly requires dissolved ferric pyrophosphate, although the final analysis would depend on the product’s actual physicochemical state.

Is ferric pyrophosphate citrate the same as ferric pyrophosphate for infringement purposes?

Not automatically. Chemical identity, formulation structure, and claim construction matter. A ferric pyrophosphate citrate product may implicate later patents specifically directed to that complex even if it does not literally satisfy every claim limitation of U.S. 6,689,275.

Can an expired patent still affect a new dialysis iron product?

Yes, as prior art and as evidence of the scope of the disclosed technology. It cannot provide a current exclusion right, but later patents may claim narrower formulations, delivery systems, manufacturing methods, or clinical uses based on related technology.

References

United States Patent and Trademark Office. (2004). U.S. Patent No. 6,689,275, Ferric pyrophosphate administration through dialysis solution.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
U.S. Food and Drug Administration. (2015). Triferic approval letter and prescribing information.
U.S. Food and Drug Administration. (2020). Triferic AVNU prescribing information.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application and 505(b)(2) application pathways.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	311180	⤷ Start Trial
Australia	5617298	⤷ Start Trial
Australia	736053	⤷ Start Trial
Brazil	9713653	⤷ Start Trial
Canada	2276442	⤷ Start Trial
Germany	69734781	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,689,275

Summary for Patent: 6,689,275